Bristol-Myers Squibb's $74 billion acquisition of Celgene would combine two troubled companies

📆 03/01/2019 23:29:00
📰 CNBC

⏱ Reading Time:
1 sec. here
2 min. at publisher
📊 Quality Score:
News: 4%
Publisher: 72%

España Noticias Noticias

España Últimas Noticias,España Titulares

Heavy debt, faltering in 2018, and cracks in the deal: Bristol-Myers Squibb's $74 billion acquisition of Celgene combines 2 troubled companies.

Hemos resumido esta noticia para que puedas leerla rápidamente. Si estás interesado en la noticia, puedes leer el texto completo aquí. Leer más:

Escribir Comentario

That's like merging Deutsche Bank and Commerzbank. Guess 1-(-1) = 2

España Últimas Noticias, España Titulares

Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.

Bristol-Myers takes $74 bln bet against the marketThere are good reasons to buy rival oncology giant Celgene. But cost cuts don’t cover the 54 pct premium and the target’s owners get the financial benefit. Bristol is hoping for luck in the courts and multiple regulatory approvals that Celgene’s shareholders were skeptical of.
Fuente: Breakingviews - 🏆 470. / 51 Leer más »